PATENT COOPERATION TREATY

10559886

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER		see Form PCT/ISA/220
PN0380-PCT	ACTION		as, where applicable, item 5 below.
International application No.	International filing date (day/month/	year)	(Earliest) Priority Date (day/month/year)
PCT/NO2004/000335	05/11/2004		06/11/2003
Applicant			
AMERSHAM HEALTH AS			
This International Search Report has beer according to Article 18. A copy is being tra	n prepared by this International Searc Insmitted to the International Bureau.	hing Auth	ority and is transmitted to the applicant
This International Search Report consists	of a total ofshee	ts.	
It is also accompanied by	a copy of each prior art document cit	ed in this i	report.
Basis of the report			
a. With regard to the language, the language in which it was filed, unl	international search was carried out of ess otherwise indicated under this ite	n the bas m.	is of the international application in the
The international this Authority (Ru		f a transla	ation of the international application furnished to
b. X With regard to any nucleo	otide and/or amino acid sequence o	lisclosed i	in the international application, see Box No. I.
2. X Certain claims were fou	nd unsearchable (See Box II).		
3. X Unity of invention is lac	king (see Box III).		
4. With regard to the title ,			
the text is approved as su			
<u> </u>	hed by this Authority to read as follow		37
CONJUGATES OF ANGIOTES	NSIN II AND AN IMAGING	MOTET	Y
5. With regard to the abstract,			
the text is approved as su	bmitted by the applicant.		
X the text has been establis may, within one month from	thed, according to Rule 38.2(b), by thing the date of mailing of this internation	s Authority onal searc	y as it appears in Box No. IV. The applicant th report, submit comments to this Authority.
6. With regard to the drawings , a. the figure of the drawings to be p	oublished with the abstract is Figure N	0.	
as suggested by			
	is Authority, because the applicant fai	ed to sug	gest a figure.
lI	is Authority, because this figure better		
b. X none of the figures is to b	e published with the abstract.		

International application No.

PCT/NO2004/000335

Box N	lo. I	N	ucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)
1.	With	regard	to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ne international search was carried out on the basis of:
	a.	x	f material a sequence listing table(s) related to the sequence listing
	b.	format X X	in written format in computer readable form
	c.	time o	f filing/furnishing contained in the international application as filed filed together with the international application in computer readable form furnished subsequently to this Authority for the purpose of search
2.	х	ar fi	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed urnished, the required statements that the information in the subsequent or additional copies is identical to that in the discation as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.	Addi	tional c	omments:

International application No.

PCT/NO2004/000335

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The invention comprises pharmaceuticals of formula (I)

 $Z-(L)_{n}-V$ (I)

wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis and are also useful as diagnostic agents for the diagnosis of heart failure and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis.

The novel pharmaceuticals comprise a targeting moiety that binds to a receptor that may or may not be up-regulated and/or over-expressed in the diseased area. The targeting moiety comprises a group which for imaging agents carry a diagnostically imageable moiety, an optional linker group and a peptide moiety.

The novel pharmaceutical compounds have high affinity for the Angiotensin Receptors, in particularly for the Angiotensin II (Ang II) type 1 (AT₁) receptor.

International application No. PCT/N02004/000335

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 10 is directed to a diagnostic method practised on the human/animal body, a search has been carried out, based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-11 in part
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-11 in part

Pharmaceutical according to claims 1-8, kit according to claim 11, and their use in a method of diagnosis and/or treatment of heart failure.

2. claims: 1-9 and 11 in part

Pharmaceutical according to claims 1-8, kit according to claim 11, and their use in a method of diagnosis and/or treatment of cardiac arrhythmias

3. claims: 1-11 in part

Pharmaceutical according to claims 1-8, kit according to claim 11, and their use in a method of diagnosis and/or treatment of COPD.

4. claims: 1-11 in part

Pharmaceutical according to claims 1-8, kit according to claim 11, and their use in a method of diagnosis and/or treatment of liver fibrosis.

5. claims: 1-11 in part

Pharmaceutical according to claims 1-8, kit according to claim 11, and their use in a method of diagnosis and/or treatment of atherosclerosis.

International Application No PCT/N02004/000335

a. classification of subject matter A61K51/08 A61K49/00

A61P1/16

A61P9/10

A61P9/00

A61P9/06

A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{tabular}{ll} \begin{tabular}{ll} Minimum documentation searched (classification system followed by classification symbols) \\ A61K \end{tabular}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, Sequence Search, CHEM ABS Data

NTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
WO 98/18496 A (NYCOMED IMAGING AS; COCKBAIN, JULIAN; KLAVENESS, JO; NAEVESTAD, ANNE;) 7 May 1998 (1998-05-07) page 2, paragraph 1 page 6, paragraph 1 claims	1-11
WO 02/064734 A (PALATIN TECHNOLOGIES, INC; SHARMA, SHUBH, D; SHI, YI-QUN) 22 August 2002 (2002-08-22)	1,3,8,11
sequences 159,162-165	1-11
WO 97/10852 A (INSTITUT FUER DIAGNOSTIKFORSCHUNG GMBH AN DER FREIE; DINKELBORG, LUDGE) 27 March 1997 (1997-03-27)	1,3,6,8,
examples claims 5,13	1-11
	Citation of document, with indication, where appropriate, of the relevant passages WO 98/18496 A (NYCOMED IMAGING AS; COCKBAIN, JULIAN; KLAVENESS, JO; NAEVESTAD, ANNE;) 7 May 1998 (1998-05-07) page 2, paragraph 1 page 6, paragraph 1 claims WO 02/064734 A (PALATIN TECHNOLOGIES, INC; SHARMA, SHUBH, D; SHI, YI-QUN) 22 August 2002 (2002-08-22) sequences 159,162-165 WO 97/10852 A (INSTITUT FUER DIAGNOSTIKFORSCHUNG GMBH AN DER FREIE; DINKELBORG, LUDGE) 27 March 1997 (1997-03-27) examples

Further documents are listed in the continuation of box 6.	A don't family morroers are listed in affiles.
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
16 November 2005	1 0. 03. 2006
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Dullaart, A

International Application No
PCT/N02004/000335

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
91		
X	DE 195 36 783 A1 (INSTITUT FUER DIAGNOSTIKFORSCHUNG GMBH AN DER FREIEN UNIVERSITAET BERL) 27 March 1997 (1997-03-27)	1,3,6,8,
Υ	example 5 claims	1-11
x	KATUGAMPOLA SIDATH D ET AL: "Changes in ETA-, AT1- and AT2-receptors in the phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries" JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 36, no. 5, Supplement 1, 2000, pages S395-S396, XP008054675 ISSN: 0160-2446 abstract page S396	1-3,6, 8-11
x	SATO TAKAYA ET AL: "Quantitative receptor autoradiographic analysis for angiotensin II receptors in bovine retinal microvessels: Quantitation with radioluminography" CELLULAR AND MOLECULAR NEUROBIOLOGY, vol. 13, no. 3, 1993, pages 233-245, XP008054685	1,3,6,8
Y	ISSN: 0272-4340 abstract page 241, paragraph DISCUSSION - page 243	1-8,11
X	HEALY D P ET AL: "LOCALIZATION OF CENTRAL ANGIOTENSIN II RECEPTORS WITH IODINE-125 SAR-1 ILE-8-ANGIOTENSIN II PERIVENTRICULAR SITES OF THE ANTERIOR THIRD VENTRICLE" NEUROENDOCRINOLOGY, vol. 44, no. 1, 1986, pages 15-21, XP008054687	1,3,6,8
Y	ISSN: 0028-3835 abstract figures 3-6 page 17, right-hand column, paragraph 2 - page 18, left-hand column, paragraph 1 page 19, right-hand column, last paragraph - page 20, left-hand column, last line	1-8,11
X	SHIGEMATSU K ET AL: "Autoradiographic evidence of angiotensin II binding sites in the human adrenal gland" BIOMEDICAL RESEARCH 1988 JAPAN, vol. 9, no. 1, 1988, pages 27-31, XP008054681	1,3,6,8
Υ	ISSN: 0388-6107 abstract page 28, paragraph RESULTS	1-8,11

International Application No
PCT/N02004/000335

tion) DOCUMENTS CONSIDERED TO BE RELEVANT	Doloupet to also to \$1.
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
SPETH R C ET AL: "Angiotensin II receptor localization in the canine CNS" BRAIN RESEARCH 1985 NETHERLANDS, vol. 326, no. 1, 1985, pages 137-143,	1,3,6,8
abstract page 140, paragraph RESULTS - page 141; figures	1-8,11
BAGBY SUSAN P ET AL: "ANG II AT(1) and AT(2) receptors in developing kidney of normal microswine." AMERICAN JOURNAL OF PHYSIOLOGY. RENAL PHYSIOLOGY. OCT 2002, vol. 283, no. 4, October 2002 (2002-10), pages F755-F764, XP002354300	1,3,6,8
ISSN: 0363-612/ abstract figures	1-8,11
SERNERI G G ET AL: "Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function." CIRCULATION RESEARCH, vol. 88, no. 9, 11 May 2001 (2001-05-11), pages 961-968, XP002354301 ISSN: 1524-4571 abstract	1-11
WO 03/051859 A (AMERSHAM PLC; BOUVET, DENIS, RAYMOND, CHRISTOPHE; WADSWORTH, HARRY, JO) 26 June 2003 (2003-06-26) examples claims	1,3-8,11
WO 03/006491 A (AMERSHAM HEALTH AS; CUTHBERTSON, ALAN; INDREVOLL, BAARD; SOLBAKKEN, MA) 23 January 2003 (2003-01-23) examples claims	1,3-8,11
WO 03/006070 A (AMERSHAM PLC; ARCHER, COLIN, MILL; WADSWORTH, HARRY, JOHN; ENGELL, TOR) 23 January 2003 (2003-01-23) examples claims	1,3-8,11
	SPETH R C ET AL: "Angiotensin II receptor localization in the canine CNS" BRAIN RESEARCH 1985 NETHERLANDS, vol. 326, no. 1, 1985, pages 137-143, XP008054668 abstract page 140, paragraph RESULTS - page 141; figures BAGBY SUSAN P ET AL: "ANG II AT(1) and AT(2) receptors in developing kidney of normal microswine." AMERICAN JOURNAL OF PHYSIOLOGY. RENAL PHYSIOLOGY. OCT 2002, vol. 283, no. 4, October 2002 (2002-10), pages F755-F764, XP002354300 ISSN: 0363-6127 abstract figures SERNERI G G ET AL: "Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function." CIRCULATION RESEARCH, vol. 88, no. 9, 11 May 2001 (2001-05-11), pages 961-968, XP002354301 ISSN: 1524-4571 abstract WO 03/051859 A (AMERSHAM PLC; BOUVET, DENIS, RAYMOND, CHRISTOPHE; WADSWORTH, HARRY, JO) 26 June 2003 (2003-06-26) examples claims WO 03/006491 A (AMERSHAM HEALTH AS; CUTHBERTSON, ALAN; INDREVOLL, BAARD; SOLBAKKEN, MA) 23 January 2003 (2003-01-23) examples claims WO 03/006070 A (AMERSHAM PLC; ARCHER, COLIN, MILL; WADSWORTH, HARRY, JOHN; ENGELL, TOR) 23 January 2003 (2003-01-23) examples

International Application No
PCT/N02004/000335

		1 017 11020047 000333
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Dolovost to state Na
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HEPPELER A ET AL: "RECEPTOR TARGETING FOR TUMOR LOCALISATION AND THERAPY WITH RADIOPETIDES" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 7, no. 9, 2000, pages 971-994, XP000982225 ISSN: 0929-8673 page 974 - page 976	1,3,8,11
Y	HENZE M ET AL: "PET imaging of somatostatin receptors using" JOURNAL OF NUCLEAR MEDICINE, NEW YORK, NY, US, vol. 42, no. 7, July 2001 (2001-07), pages 1053-1056, XP002245466 ISSN: 0161-5505 abstract page 1054, left-hand column	1,3,8,11
Y	WO 98/18498 A (MARSDEN, JOHN, CHRISTOPHER; NYCOMED IMAGING AS; KLAVENESS, JO; RONGVED) 7 May 1998 (1998-05-07) examples claims	1,3,8,11

Information on patent family members

International Application No
PCT/N02004/000335

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9818496	Α	07-05-1998	EP	0971747	A2	19-01-2000
WO 02064734	A	22-08-2002	CA EP JP	2436789 1379283 2005501220	A2	22-08-2002 14-01-2004 13-01-2005
WO 9710852	A	27-03-1997	AU CA DE EP	1435997 2232391 19536781 0853488	A1 A1	09-04-1997 27-03-1997 27-03-1997 22-07-1998
DE 19536783	A1	27-03-1997	AU CA WO EP	1300597 2232340 9710853 0851771	A1 A2	09-04-1997 27-03-1997 27-03-1997 08-07-1998
WO 03051859	A	26-06-2003	AT AU DE EP JP US	310736 2002350950 60207612 1463721 2005516935 2005080130	A1 D1 A1 T	15-12-2005 30-06-2003 29-12-2005 06-10-2004 09-06-2005 14-04-2005
wo 03006491	A	23-01-2003	BR CA CN EP HU JP MX PL US	0210886 2452923 1622830 1404371 0400974 2005507376 PA04000173 367273 2005070466	A1 A A2 A2 T A	22-06-2004 23-01-2003 01-06-2005 07-04-2004 30-08-2004 17-03-2005 18-03-2004 21-02-2005 31-03-2005
WO 03006070	A	23-01-2003	AT BR CA CN DE DK EP HK HU JP MX US ZA	304866 0210965 2450690 1527727 60206272 1404377 1404377 1064585 0401265 2005500325 PA04000210 2004258619 200400143	A A1 A D1 T3 A2 A1 A2 T A	15-10-2005 08-06-2004 23-01-2003 08-09-2004 27-10-2005 30-01-2006 07-04-2004 11-11-2005 28-09-2004 06-01-2005 23-07-2004 23-12-2004 14-10-2004
WO 9818498	Α	 07-05-1998	EP	0963209	A2	15-12-1999